MedTrace Logo

Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus

NCT00372957 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-09-04

Study results available
· View outcomes & findings →

Summary

To investigate the preliminary pharmacokinetics, pharmacodynamics, safety and tolerability of GW823093 at doses of 15mg and 30mg given once daily for 7 days in Japanese Type 2 diabetes mellitus (T2DM) patients.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

GW823093 15mg

White opaque capsule containing 15mg of GW823093 as free base

DRUG

GW823093 placebo capsule

Matching placebo of GW823093 capsule or 15mg capsule

DRUG

GW823093 30mg

White opaque capsule containing 15mg of GW823093 as free base

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-22
Primary Completion
2006-06-28
Completion
2006-06-28

Countries

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00372957 on ClinicalTrials.gov